SA Cancer Diagnostic Company Adding Research Talent
DECEMBER 23, 2022
As published in the San Antonio Business Journal
By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal
BioAffinity Technologies Inc. is making multiple personnel moves in an effort to strengthen its core division and expand its research capabilities.
The San Antonio-based company, which is working to commercialize its anchor technology, the CyPath Lung early cancer detection system, has promoted Jennifer Rebeles to vice president of diagnostics while adding Rossella Titone and Alvaro Souto Padron de Figueiredo to the division’s scientific team.
Rebeles joined bioAffinity (Nasdaq: BIAF; BIAFW) in 2019 as director of diagnostics where she led the company’s research team in the development of CyPath Lung. Prior to that, she was a research scientist with the United States Air Force’s 59th Medical Wing for Science and Technology. She was also previously a director at the Greehey Children’s Cancer Research Institute at UT Health San Antonio.
“Dr. Rebeles has shown exceptional leadership and scientific acumen in the development and commercialization of CyPath Lung,” said Dr. Vivienne Rebel, who is both an executive vice president, as well as chief medical and science officer for bioAffinity.
Titone joins bioAffinity from the Texas Biomedical Research Institute, which is also in San Antonio, where she was a postdoctoral scientist.
Dr. Souto Padron de Figueiredo was previously in the Division of Hematology & Oncology at UT Health San Antonio, where he worked on a National Institute of Health-funded research grant and tested new drugs for pharmaceutical companies.
“These men and women are innovative, dedicated and committed to the commercialization of CyPath Lung and development of additional diagnostics for lung diseases and tests for cancer,” bioAffinity President and CEO Maria Zannes said.
BioAffinity wrapped up an initial public offering in the fall that’s funneled nearly $16 million into the company.
In November, I noted that bioAffinity, in its first quarterly filing as a public company, reported a net loss of $4.9 million. Zannes attributed most of that to expenses tied to ongoing research to commercialize CyPath Lung.
